# Armando Santoro

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/armando-santoro/

## Facts

| Field | Value |
| --- | --- |
| Citations | 78,732 |
| Field | Lymphoma Diagnosis and Treatment |
| h-index | 122 |
| i10-index | 690 |
| Last Known Institution | IRCCS Humanitas Research Hospital |
| OpenAlex ID | https://openalex.org/A5100766578 |
| ORCID iD | https://orcid.org/0000-0003-1709-9492 |
| Works | 1,842 |

## Researcher papers

- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial](https://scholariq.org/papers/lurbinectedin-as-second-line-treatment-for-patients-with-small-cell-lung-cancer/)
- [Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial](https://scholariq.org/papers/activity-and-safety-of-ceritinib-in-patients-with-alk-rearranged-non-small-cell/)
- [Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma](https://scholariq.org/papers/safety-and-antitumor-activity-of-the-anti-pd-1-antibody-pembrolizumab-in/)
- [Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation](https://scholariq.org/papers/clinical-effects-of-driver-somatic-mutations-on-the-outcomes-of-patients-with/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)
- [Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy](https://scholariq.org/papers/phase-ii-study-of-everolimus-in-patients-with-thymoma-and-thymic-carcinoma/)

## Researcher topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [IRCCS Humanitas Research Hospital](https://scholariq.org/institutions/irccs-humanitas-research-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.